We narrowed to 3,492 results for: cre recombinase
-
Plasmid#224196PurposeAiE0784m is an enhancer sequence, designed to drive Cre dependent AAV-mediated transgene expression in striatal MSNsDepositorInsertCoChR-EGFP
UseAAVAvailable SinceSept. 25, 2024AvailabilityAcademic Institutions and Nonprofits only -
AiP13729 - pAAV-AiE0447h-minBG-DIO-SYFP2-WPRE3-BGHpA (Alias: CN3729)
Plasmid#191734PurposeAI plasmid ALIAS: AiP13729. Cre dependent expression of SYFP2 (yellow fluorescent protein) restricted to striatal medium spiny neuronsDepositorInsertSYFP2
UseAAVMutationnoneAvailable SinceFeb. 1, 2024AvailabilityAcademic Institutions and Nonprofits only -
pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (AAV2)
Viral Prep#112677-AAV2PurposeReady-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmCherry (Cre-negative cells), EGFP (Cre-positive cells)Available SinceJan. 17, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-nEF-Con/Foff DREADD Gi-mCherry (AAV8)
Viral Prep#177673-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.DepositorPromoternEFTagsmCherryAvailable SinceFeb. 16, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-FLEX-EGFP (AAV1)
Viral Prep#59331-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-CAG-FLEX-EGFP (#59331). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-EGFP plasmid DNA. CAG-driven, Cre-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEGFPAvailable SinceJuly 12, 2023AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-iCreV (AAV PHP.eB)
Viral Prep#140135-PHPeBPurposeReady-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceSept. 15, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn-Flex-Axon-EGFP (AAV1)
Viral Prep#135429-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-hSyn-Flex-Axon-EGFP (#135429). In addition to the viral particles, you will also receive purified pAAV-hSyn-Flex-Axon-EGFP plasmid DNA. Syn-driven, Cre-dependent expression of axon-targeted EGFP control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsEGFP (Cre-dependent)Available SinceMarch 19, 2021AvailabilityAcademic Institutions and Nonprofits only -
rAAV-CAG::FLEX-rev:: hM4D-2a-GFP (AAV1)
Viral Prep#52536-AAV1PurposeReady-to-use AAV1 particles produced from rAAV-CAG::FLEX-rev:: hM4D-2a-GFP (#52536). In addition to the viral particles, you will also receive purified rAAV-CAG::FLEX-rev:: hM4D-2a-GFP plasmid DNA. CAG driven, Cre-dependent expression of hM4D and GFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFPAvailable SinceDec. 18, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (AAV5)
Viral Prep#209655-AAV5PurposeReady-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (#209655). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of the high affinity ATP biosensor iATPSnFR2. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGAvailable SinceOct. 21, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-flex-taCasp3-TEVp (AAV1)
Viral Prep#45580-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceDec. 3, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-flex-taCasp3-TEVp (AAV8)
Viral Prep#45580-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceNov. 13, 2025AvailabilityAcademic Institutions and Nonprofits only -
pAAV-TRE-DIO-eYFP (AAV1)
Viral Prep#117383-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-TRE-DIO-eYFP (#117383). In addition to the viral particles, you will also receive purified pAAV-TRE-DIO-eYFP plasmid DNA. Tet-inducible, Cre-dependent eYFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterTRETagseYFP (Tet-inducible, Cre-dependent)Available SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (AAV8)
Viral Prep#137149-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (#137149). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of Arch3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.DepositorPromoternEFTagsEYFP (Cre-dependent)Available SinceMay 6, 2021AvailabilityAcademic Institutions and Nonprofits only -
pGP-AAV-syn-flex-iGABASnFR2-WPRE (AAV5)
Viral Prep#218877-AAV5PurposeReady-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynAvailable SinceSept. 27, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-DIO-EYFP (AAV PHP.V1)
Viral Prep#104052-AAVPHP.V1PurposeReady-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEYFP (Cre-dependent)Available SinceJuly 24, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-mitoGFP-DIO (AAV2)
Viral Prep#174112-AAV2PurposeReady-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceAug. 7, 2025AvailabilityAcademic Institutions and Nonprofits only -
pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (AAV1)
Viral Prep#169128-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceAug. 7, 2025AvailabilityAcademic Institutions and Nonprofits only -
pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (AAV1)
Viral Prep#98932-AAV1PurposeReady-to-use AAV1 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGAvailable SinceFeb. 28, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-DIO mScarlet (AAV5)
Viral Prep#131002-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmScarlet (Cre-dependent)Available SinceSept. 27, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-4mtGCaMP6f-DIO (AAV1)
Viral Prep#179529-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-EF1a-4mtGCaMP6f-DIO (#179529). In addition to the viral particles, you will also receive purified pAAV-EF1a-4mtGCaMP6f-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GCaMP8f. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aAvailable SinceFeb. 6, 2026AvailabilityAcademic Institutions and Nonprofits only